ArticleJACC. CardioOncology2026
Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy.
Article in JACC. CardioOncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cardiovascular Toxicity Associated With Bispecific Antibodies in Hematological Malignancies: A Comprehensive Pharmacovigilance Analysis.American journal of hematology · 2026Article
- The New Cardio-Oncology Frontier in Hematologic Cancers: Cardiovascular Toxicities of CAR-T Cells and Bispecific T-Cell Engagers.Journal of clinical medicine · 2026Review
- Cardiovascular Safety of T Cell Engagers: Reassuring Overall, But Not Benign for All.JACC. CardioOncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough some cancer immunotherapies have been linked to increased cardiovascular risk, data on T-cell engager (TCE) therapy-associated cardiovascular complications remain limited.
objectivesThis study sought to characterize the incidence and factors associated with cardiovascular events (CVEs) and mortality during TCE therapy.
methodsWe conducted a dual-center retrospective study of patients with cancer treated with TCEs between 2016 and 2024. The cumulative incidence of on-treatment CVEs (heart failure, arrhythmias, myocardial infarction, stroke) and cardiovascular mortality was evaluated using Fine-Gray competing-risks models incorporating time-dependent grade ≥2 cytokine-release syndrome (CRS) and/or immune effector cell-associated neurotoxicity syndrome (ICANS). Factors associated with all-cause mortality were assessed using Cox models including CVEs as a time-dependent covariate.
resultsAmong 567 patients (median age 67 years [Q1-Q3: 57-75]; 46.0% female), 25.9% had preexisting cardiovascular disease. The most common malignancies were multiple myeloma (40.9%) and acute lymphoblastic leukemia (35.6%). The restricted mean follow-up was 248 days (range: 0-973), during which 65 CVEs occurred (cumulative incidence 10.4%; 95% CI: 8.1-13.1), most commonly new left ventricular dysfunction (2.3%) and new-onset atrial fibrillation (2.1%). Cardiovascular mortality was rare (2 cases, 0.4%). Coronary artery disease was the only baseline variable independently associated with CVEs, whereas development of grade ≥2 CRS and/or ICANS was associated with a significant time-dependent increase in CVE risk. CVEs were significantly associated with higher all-cause mortality, independent of baseline clinical factors and TCE agent.
conclusionsTCE therapy demonstrates a favorable cardiovascular safety profile overall, yet cardiovascular complications during therapy are associated with markedly increased mortality risk. Patients with preexisting coronary artery disease and those who develop high-grade CRS and/or ICANS represent high-risk groups that may benefit from intensified cardiovascular assessment and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.